HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome

Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.

By FierceBiotech · Jun 1, 2026 · via FierceBiotech
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
The WeekFiercePharma ↗
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?
Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already …
Jun 1, 2026
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
The WeekBriefing
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
Jun 1, 2026
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
The WeekBioPharma Dive ↗
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline…
Jun 1, 2026